Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.59 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842057 | 0.94 | APP (0.57) | LTA4HNR5A1APPMAPTDRD2 | |
| SCHEMBL1478767 | 0.94 | APP (0.57) | LTA4HNR5A1APPMAPTDRD2 | |
| SCHEMBL16305613 | 0.94 | APP (0.57) | LTA4HNR5A1APPMAPTDRD2 | |
| SCHEMBL7917011 | 0.94 | ESR2 (0.57) | LTA4HNR5A1APPMAPTDRD2 | |
| SCHEMBL12264007 | 0.90 | PTPN1 (0.57) | LTA4HNR5A1APPDRD4CYP1A2 | |
| SCHEMBL10879381 | 0.89 | LTA4H (0.62) | LTA4HNR5A1APPDRD2DRD4 | |
| SCHEMBL11601640 | 0.89 | NR5A1 (0.68) | LTA4HNR5A1APPDRD2DRD4 | |
| SCHEMBL16305604 | 0.89 | APP (0.53) | LTA4HNR5A1APPESR2 | |
| SCHEMBL226548 | 0.88 | LTA4H (0.64) | LTA4HNR5A1APPDRD2DRD4 | |
| SCHEMBL8339774 | 0.88 | MAPT (0.52) | LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-4816604-A | CARDIOVASCULAR DISORDERS | Louis, William J. (AU) | 1989-03-28 | — | — | US | disclosed |
| WO-1989000849-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1989-02-09 | — | — | WO | disclosed |
| US-4636501-A | ADRENERGIC BETA BLOCKERS | AKTIEBOLAGET HASSLE (SE) | 1987-01-13 | — | — | US | disclosed |
| EP-0085286-B1 | PARA-SUBSTITUTED 3-PHENOXY-1-CARBONYLAMINOALKYLAMINO-PROPAN-2-OLS HAVING BETA RECEPTOR BLOCKING PROPERTIES | Aktiebolaget Hässle (SE) | 1986-04-30 | — | — | EP | disclosed |
| EP-0083839-B1 | PROCESS FOR PRODUCING INORGANIC FIBER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0052072-B1 | 3-AMINOPROPOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ AG (CH) | 1985-02-20 | — | — | EP | disclosed |
| US-4495121-A | SPINNING A POLYMETALOXANE, CALCINING | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1985-01-22 | — | — | US | disclosed |
| US-4425362-A | CARDIOVASCULAR DISORDERS, ADRENERGIC BLOCKING AGENTS | SANDOZ LTD. (CH) | 1984-01-10 | — | — | US | disclosed |
| EP-0085286-A1 | Para-substituted 3-phenoxy-1-carbonylaminoalkylamino-propan-2-ols having beta receptor blocking properties | Aktiebolaget Hässle (SE) | 1983-08-10 | — | — | EP | disclosed |
| US-3949088-A | Substituted phenoxy propanol amines used for treating cardiovascular diseases | SAMUELSSON BENNY ROGER | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | LTA4H 1754/4885NR5A1 523/4885APP 4605/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | LTA4H 846/4885NR5A1 3862/4885APP 3938/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | LTA4H 433/4885NR5A1 3146/4885APP 3516/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | LTA4H 299/4885NR5A1 4154/4885APP 3148/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | LTA4H 846/4885NR5A1 3862/4885APP 3938/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | LTA4H 2979/4885NR5A1 4276/4885APP 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.